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Abstract 
Long-lasting neuroadaptations in the glutamatergic corticostriatal circuitry have been suggested to be 
responsible for the persisting nature of drug addiction. In particular, animal models have linked the 
metabotropic glutamate receptor 5 (mGluR5) to drug-seeking behavior and extinction learning. 
Accordingly, blocking mGluR5s attenuated self-administration of cocaine and other addictive drugs in 
rats. How these animal findings extend to humans remains unclear. Therefore, we investigated if 
human cocaine users exhibit altered mGluR5 availability compared to drug-naïve control subjects. 
Seventeen male controls (11 smokers) and 18 male cocaine users (13 smokers) underwent positron 
emission tomography with 11C-ABP688 to quantify mGluR5 availability in 12 volumes of interest in 
addiction-related brain areas. Drug use was assessed by self-report and quantitative hair toxicology.  
Cocaine users and controls did not significantly differ in regional mGluR5 availability. In contrast, 
smokers (n=24) showed significantly lower mGluR5 density throughout the brain (mean 20%) 
compared to non-smokers (n=11). In terms of effect sizes, lower mGluR5 availability was most 
pronounced in the caudate nucleus (d=1.50, 21%), insula (d=1.47, 20%), and putamen (d=1.46, 18%). 
Duration of smoking abstinence was positively associated with mGluR5 density in all brain regions of 
interest, indicating that lower mGluR5 availability was particularly pronounced in individuals who had 
smoked very recently. 
Specifically tobacco smoking was associated with lower mGluR5 availability in both cocaine users 
and controls, while cocaine use was not linked to detectable mGluR5 alterations. These findings have 
important implications regarding the development of novel pharmacotherapies aimed at facilitating 
smoking cessation. 
 
Keywords: addiction, glutamate, PET, cocaine, nicotine, treatment 
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Introduction 
Cocaine addiction continues to be a major public health concern resulting in high societal and 
economic costs.1,2 Notably, cocaine is the second most used illicit drug with 13 to 20 million users 
worldwide. Annual prevalence rates are relatively high with 1.6% in North America, 1.3% in Central 
Europe, and 1.5-1.9% in Oceania3 and the harmful effects associated with cocaine use also become 
evident through the high treatment demand related to psychostimulants. Accordingly, 17% of all 
patients who entered drug treatment programs in the USA,4 and 23% of the drug-seeking patients in 
Europe did so for the treatment of stimulant addiction.5 Despite the high treatment demand, effective 
pharmacotherapies for cocaine addiction are currently lacking.6 
While acutely reinforcing effects of addictive drugs are mainly dependent on the 
mesocorticolimbic dopamine system,7 accumulating preclinical research has provided evidence that 
longer-lasting neuroadaptations in glutamatergic corticolimbic circuitries may be responsible for the 
persisting nature of cocaine addiction.8-10 In particular, glutamatergic projections from the prefrontal 
cortex (PFC) to the nucleus accumbens (NAcc) appear to be relevant for drug reinstatement and drug-
seeking behavior in animals and may also play an important role in craving and relapse-related 
behaviors in psychostimulant-addicted humans.9,11 Chronic self-administration in rats resulted in lower 
basal extracellular, non-synaptic glutamate levels in the NAcc, which in turn has been associated with 
down-regulation of group I and II metabotropic glutamate receptor (mGluR) expression and function 
in rats,12-17 resulting in altered synaptic plasticity. Impaired plasticity has been suggested to contribute 
to the relative inability to form adaptive behaviors that help inhibiting relapse in drug users.9 
The mGluR of type 5 (mGluR5), belonging to group I mGluRs, has gained growing attention in 
addiction research due to its high expression in corticolimbic regions implicated in drug addiction18 
and involvement in drug-seeking behavior and extinction learning in animals withdrawn after cocaine 
self-administration (for reviews19,20). In fact, mGluR5 null-mutant mice neither self-administered 
cocaine nor exhibited increased locomotor activity after cocaine treatment.21 Moreover, self-
administration and reinstatement of cocaine, nicotine, alcohol, methamphetamine, and heroin was 
attenuated by mGluR5 antagonists.22-32 Therefore, much effort is being undertaken to develop 
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pharmacological compounds with the ability to block mGluR5s, which is assumed to be one 
efficacious way to treat psychostimulant-addiction. 
How preclinical findings regarding changes in mGluR5 expression extend to human cocaine 
users (CU) has not been investigated to date. The positron emission tomography (PET) radioligand 
11C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-enone-O-carbon-11-methyl-oxime)33,34 has 
made it possible to quantify mGluR5 availability in humans. A recent PET study applying this ligand 
has demonstrated that smokers exhibit globally lower cerebral mGluR5 density.35 However, it is not 
clear if mGluR5 alterations are specific for nicotine addiction or a common phenomenon in drug 
addiction. Therefore, the aim of the present study was to quantify mGluR5 availability in addiction-
related brain regions employing 11C-ABP688 PET in CU and drug-naïve controls. Additionally, we 
investigated the potential impact of smoking on mGluR5 availability in CU. We expected that both 
cocaine and tobacco use decrease mGluR5 availability in corticolimbic brain regions. 
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Materials and Methods 
Participants 
The study sample consisted of 18 male drug-naïve healthy control subjects (HC) and 18 male 
CU who also took part in the longitudinal Zurich Cocaine Cognition Study (ZuCo2St).36-38 Participants 
were recruited via advertisements in local newspapers, different drug prevention and treatment centers, 
psychiatric hospitals, internet platforms, and word-of-mouth communication (for details see37). 
Inclusion criteria for CU were 1) diagnoses of cocaine abuse or dependence according to DSM-IV,39 
2) age between 20 to 50 years, 3) proficiency in German language, 4) no polytoxic drug use pattern 
and no use of prescription drugs affecting the CNS, 5) no current or previous Axis I DSM-IV 
psychiatric disorder (other than cocaine abuse/dependence, alcohol abuse in CU, and a former 
depression), 6) no neurological disorder or head injury, 7) no family history of a severe DSM-IV 
psychiatric disorder such as schizophrenia, bipolar disorder or obsessive-compulsive disorder, and 8) 
no metal parts in the body. The same inclusion criteria applied to HC except for 1). Additionally, HC 
were excluded if they regularly engaged in illegal drug use (>15 occasions) with exception of cannabis 
use. Participants were instructed to abstain from illegal drugs for ≥3 days and ≥24 hours from alcohol. 
Urine samples were collected to control for recent drug use. To objectively characterize drug use over 
the past six months, hair samples (6cm) were collected and analyzed with liquid chromatography-mass 
spectrometry (see Supplement). Participants received financial compensation. This study was 
approved by the Ethics Committee of the Canton Zurich and the Swiss Federal Office of Public 
Health. All participants provided written informed-consent before inclusion. 
 
Clinical Interviews and Questionnaires 
The Structured Clinical Interview for DSM-IV Disorders was carried out by a trained 
psychologist.39 Drug use was assessed by means of the Interview for Psychotropic Drug Consumption, 
which has been described in detail elsewhere.40 The Beck Depression Inventory (BDI) was used to 
assess symptoms of depression.41 The Symptom Checklist-90-R (SCL-90-R) served as a screening 
measure of general psychiatric symptoms.42 The brief version of the Cocaine Craving Questionnaire 
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(CCQ) was used to assess current cocaine craving.43,44 The Fagerström Test for Nicotine Dependence 
(FTND) was used to determine severity of nicotine dependence.45 
 
Image Acquisition and Data Analyses 
Magnetic Resonance Image Acquisition. T1-weighted magnetic resonance (MR) imaging was 
acquired for each participant on a Philips Achieva 3T whole-body scanner equipped with a 
transmit/receive head coil (Philips Healthcare, Best, The Netherlands) to rule out structural 
abnormalities and for the preprocessing of PET images. 
 
PET Acquisition. The synthesis of 11C-ABP688 has been described in detail elsewhere.33,34 PET 
image acquisition was conducted in 3-D mode in the whole-body scanner DSTX PET/computed 
tomography scanner (B. Braun Medical, Sempach, Switzerland) at the Division of Nuclear Medicine 
of the University Hospital Zurich. Before the PET acquisition, a catheter was placed in the left 
antecubital vein for tracer injection and a low-dose CT was conducted for attenuation correction. In 
order to avoid inconvenient arterial blood sampling, we relied on a previously evaluated equilibrium 
paradigm46,47 based on the premise that a steady-state between tracer concentration in tissue and blood 
can be obtained.48,49 11C-ABP688 was administered according to a bolus-infusion protocol,46,49 where 
half of the tracer was administered as a bolus over 2min and the other half was infused over 58min 
(Perfusor FM, Braun Medical). Groups did not differ regarding injected activity [HC: 604±29 MBq, 
CU: 600±24 MBq, t(33)=-0.42, p=.68 (two-tailed)]. At tracer injection, a series of 20 scans was 
recorded over a total duration of 60min (10x60sec, 10x300sec). Applying filtered back-projection, 
transaxial images were reconstructed to a 128x128 matrix with 47 transaxial slices of 2.3x2.3x3.2mm 
voxel size. 
 
PET Image Processing and Quantification. Image processing and quantification steps were 
performed with the PMOD software, version 3.307 (PMOD Technologies, Zurich, Switzerland). 
Frames 17 to 19 were averaged and spatially normalized to the Montreal Neurological Institute (MNI) 
template brain. Twelve volumes of interest (VOIs) and a cerebellar reference VOI were generated 
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based on the standard VOIs of the MNI template brain50 comprising the following brain regions: ACC, 
dorsolateral PFC (DLPFC), MPFC, OFC, ventrolateral PFC (VLPFC), caudatus nucleus, putamen, 
insula, amygdala, parahippocampal gyrus, hippocampus, and thalamus.  
To verify that steady-state of receptor binding was reached after 45min (frames 17 to 19), time-
activity curves were generated for high (ACC, putamen), medium (thalamus), and low receptor density 
regions (cerebellum) in both hemispheres for all participants. Steady state of 11C-ABP688 uptake 
45min after tracer injection was reached in all participants, save one control subject, who was 
therefore excluded from the subsequent statistical analyses. Normalized values of distribution 
(Vnorm=CT[VOI]/CT[Cer]) of 11C-ABP688 uptake constituted the quantitative PET outcome measure and 
were derived by dividing the average radioactivity concentration between 45 and 55min (frames 17 to 
19) of each VOI (CT[VOI]) with the commensurate cerebellar radioactivity concentration (CT[Cer]). Vnorm 
is equivalent to BPND+1=((VT–VND)/VND)+1).51 mGluR5 has been successfully quantified with this 
approach in previous studies46,52,53 and a preclinical study showed that the cerebellum is relatively 
devoid of mGluR5 and thus suitable as a reference region.54 
 
Statistical Analysis 
Statistical analyses were performed with the PASW 19.0 software (SPSS Inc.). Independent t-
tests and frequency analyses (Pearson’s Chi2 test) were conducted to compare groups among 
demographic and clinical questionnaire data. PET data were analyzed with a mixed-effect analysis of 
variance (ANOVA) including the between-subject factors group (HC, CU) and smoking status (non-
smokers, smokers), the within-subject factors brain region (12 VOIs) and hemisphere (left, right), and 
their interactions. Two-tailed independent t-tests were conducted to identify differences of 11C-
ABP688 uptake in the selected VOIs between groups. To account for multiple testing, the Bonferroni-
correction was applied, resulting in a significance level of p<.0042 (p=.05/12). Potential associations 
of drug use parameters and mGluR5 availability were examined with correlation analyses (Pearson’s 
product-moment). Effect sizes (Cohen’s d) were calculated with G*Power 3.1.55 As the assumption of 
parametric distribution was not met by certain variables, the drug use parameters weekly alcohol, 
cigarette, cannabis and cocaine consumption (in grams/cigarettes), last alcohol, cigarette, cannabis and 
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cocaine use (h), cumulative cannabis and cocaine dose (g), and concentrations of cocaine and its 
metabolites in the hair samples (pg/mg) were log-transformed (log10) and the constant 1 was added 
because the data contained 0 values. 
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Results 
Demographic Information and Drug Use Patterns 
HC and CU were well-matched for age, smoking status, symptoms of depression, years of 
education, and did not differ with regard to SCL-90 and FTND scores (Table 1). Nine (50%) of the 
CU met the DSM-IV criteria for current cocaine dependence, while the remaining 9 CU met cocaine 
abuse criteria. Except for one CU who reported smoking crack cocaine, all other CU indicated to use 
cocaine nasally. None of the participants met the criteria for alcohol dependence. Drug use patterns are 
shown in Table 2. CU and HC did not differ in cigarette use. However, CU reported higher weekly 
alcohol consumption [t(33)=-2.84, p<.05] and higher cumulative doses of cannabis [t(33)=-2.17, 
p<.05]. CU had a mean weekly cocaine consumption of 1.5g, while they reported very little co-use of 
amphetamine and MDMA. Hair toxicology analyses capturing the past six months confirmed that 
cocaine was the primary drug of choice in all CU. Methamphetamine and opiates were not detected, 
while mean amphetamine values were very low. It is noteworthy that 44% of the CU tested positive 
for cocaine in the urine toxicology. Therefore, additional analyses were carried out to investigate post-
acute effects of cocaine use. 
 
11C-ABP688 Uptake in Controls, Cocaine Users, and Smokers 
In accordance with previous reports,34,53,56 regional 11C-ABP688 uptake was highest in mGluR5-
rich regions such as the ACC, caudate, insula, and putamen, while 11C-ABP688 binding was lower in 
the thalamus (Figure 1A/B, 2A/B). 
11C-ABP688 uptake did not differ between HC and CU (Figure 1A, 2A), yet differed 
substantially between non-smokers (n=11) and smokers (n=24)(Figure 1B, 2B). The mixed-effect 
ANOVA revealed significant main effects of smoking status [F(1,31)=29.46, p<.0001] and brain 
region [F(11,341)=127.22, p<.0001] but not of group [F(1,31)=0.09, p=.77] and hemisphere 
[F(1,31)=0.86, p=0.36]. Therefore, Vnorm values of both hemispheres were averaged for further 
calculations. Smokers showed lower (14-21%) mGluR5 availability in all VOIs compared to non-
smokers (Figure 1B, Table S1) and the effect was present in CU and controls (Figure S1). Notably, 
when only non-smoking CU (n=5) were compared with non-smoking HC (n=6), there was a weak 
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trend for lower mGluR5 availability in the caudate nucleus of CU [t(9)=1.87, p=.095, d=1.01]. 
Moreover, heavy smokers showed slightly lower mGluR5 availability than light smokers (Figure S2). 
11C-ABP688 uptake in all VOIs correlated significantly with age in CU (n=18, r=.51-.58, p<.05) 
and smokers [(n=24, 13 CU and 11 HC), r=.41-.52, p<.05; except for the hippocampus and amygdala 
p=.12] but not in HC in general (n=17, p>.88). Moreover, 11C-ABP688 uptake was significantly 
negatively associated with age in non-smokers in the putamen [(n=11, CU=5, HC=6), r=-.65, p<.05)]. 
 
Drug Use Parameters and 11C-ABP688 Uptake 
In order to reduce the probability of α-error accumulation, three combined brain regions were 
derived by averaging the Vnorm values of the OFC, ACC, MPFC, DLPFC, VLPFC (Frontal Cortex), 
the Vnorm values of the caudate and the putamen (Striatum), and the Vnorm values of the amygdala, 
parahippocampal gyrus, and the hippocampus (Medial Temporal Lobe [MTL]). The insula and the 
thalamus were not combined with other brain regions. To prevent inflating potential associations, for 
correlation analyses regarding drug use only users of the specific drug were included. 
There were no significant associations of alcohol, cannabis, and cocaine use (times/g per week, 
last use, duration in years, cumulative dose in g) with mGluR5 availability, except for age of cocaine 
onset (rStriatum VOI=.47, p=.05; rMTL VOI=.55, p<.05; rThalamus VOI=.48, p<.04). However, when corrected 
for age, these correlations were not statistically significant anymore (p>.30). Weekly cigarette 
consumption and smoking duration did not correlate with mGluR5 availability, yet last cigarette use 
(h) correlated strongly with mGluR5 availability (rFrontal VOI=.60, p<.01; rStriatum VOI=.61, p<.01; rMTL 
VOI=.57, p<.01; rInsula VOI=.63, p<.01; rThalamus VOI=.57, p<.01; Figure 3). Moreover, age of onset of 
smoking correlated positively with mGluR5 availability in the frontal VOI (r=.41, p<.05) and 
thalamus (r=.45, p<.05), but this result also did not survive correction for age (p>.31). 
Eight out of 18 CU tested positive for cocaine in the urine toxicology. Therefore, mGluR5 
availability was compared among controls (n=17), CU who tested negative (n=10), and CU who tested 
positive for cocaine (n=8). There was no significant group difference for all VOIs indicating that 
recent cocaine use did not alter mGluR5 density in CU. The same analysis was repeated with cannabis 
urine toxicology status, but recent cannabis use did also not affect our results. Cocaine craving scores 
did not correlate with mGluR5 availability in CU.
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Discussion 
This is the first study to investigate mGluR5 availability in human CU vs. psychostimulant-
naïve control subjects. The CU sample was unique in terms of very little co-use of other illicit drugs 
verified by hair toxicology, and sparse psychiatric co-morbidities. The key findings are that cocaine 
use was not significantly associated with altered mGluR5 density. However, in a small subsample of 
non-smokers, CU exhibited a trend for lower mGluR5 availability in the caudate nucleus in 
comparison to HC. In line with a recent study,35 smokers exhibited globally lower mGluR5 density of 
on average 20% compared to non-smokers. The time interval since smoking the last cigarette 
correlated with mGluR5 density in all regions of interest, reflecting that the lower mGluR5 availability 
was particularly pronounced in individuals who had smoked very recently. Interestingly, while older 
age was associated with higher mGluR5 availability in CU and smokers, an opposing trend was 
observed in non-smokers, whereas no significant correlations between age and mGluR5 availability 
were found in controls. 
With the present study, we replicated the recent finding that smoking is associated with 
markedly lower 11C-ABP688 uptake35 either representing altered affinity of the binding site or lower 
mGluR5 density. Because G-protein coupled receptors have the ability to undergo endocytosis in 
response to changes in extracellular levels of receptor agonists,57 the notion that the 20% lower 
mGluR5 availability in smokers constitutes a mechanism to attenuate excessive signaling by down-
regulation or internalization seems probable.58-60 Indeed, the fact that longer smoking abstinence was 
associated with increased mGluR5 availability may reflect the dynamic nature of mGluR5 trafficking 
and supports the assumption of nicotine-induced changes. Alternatively, reduced mGluR5 availability 
may constitute a pre-existing condition that increases the risk for nicotine dependence. The average 
mGluR5 reduction observed in our study was remarkably in accordance with recent independent 
data.35 Although mGluR5 availability was slightly lower in the caudate nucleus compared to other 
brain regions in smokers, we did not find a strong region-specific decrease as was previously revealed 
for the medial OFC in smokers.35 Moreover, cigarettes smoked per week and severity of nicotine 
dependence in our study did also not correlate with mGluR5 availability. Furthermore, we failed to 
find a significant association between smoking duration and mGluR5 availability. However, when 
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Akkus et al.35 took age into account the association was not significant either. A notable difference 
emerged with regard to smoking abstinence, where we found that briefer smoking abstinence was 
associated with lower mGluR5 availability. This divergent finding is likely explained by the fact that 
smokers exhibited a larger variance of abstinence periods in our study increasing the likelihood to 
detect significant correlations. 
mGluR5s have directly been linked to drug-seeking behavior and extinction learning in animals 
withdrawn after cocaine self-administration (for reviews19,20,61). Preclinical studies have shown that 
chronic self-administration of cocaine disrupts synaptic communication between the PFC and the 
striatum and results in decreased basal levels of non-synaptic, extracellular glutamate in the NAcc.11,62-
65 Reduced extracellular glutamate tone in the NAcc core has in turn been associated with down-
regulation of mGluR5 expression and function in rats,12-17 resulting in disrupted synaptic plasticity, 
which is assumed to contribute to the persisting nature of addiction.9 It has been proposed, that the 
observed down-regulation of mGluR5s and Homer1b/c, post-synaptic scaffolding proteins influencing 
mGluR5 trafficking and signal transduction, after chronic cocaine administration may constitute a 
compensatory mechanism, as mGluR5 antagonists attenuate drug-seeking behaviors.9 Interestingly, 
extinction training was also associated with a marked decrease in mGluR5 expression and elevated 
levels of Homer proteins, possibly providing further support for compensatory adaptation, which may 
inhibit relapse.66 Moreover, it has been suggested that genetic variations in mGluR5s, when resulting 
in decreased mGluR5-mediated neurotransmission, may render such individuals less sensitive to the 
reinforcing effects of cocaine and nicotine, as well as aversive states during withdrawal as the 
chromosomal region 11q14, on which the mGluR5 gene (GRM5) is located has been associated with 
habitual smoking behaviour.67,68 
Even though findings from preclinical and human studies are not directly comparable, it is 
noteworthy that preclinical cocaine studies found specifically reduced mGluR5 expression in the 
NAcc core and failed to find alterations in mGluR5 expression in the PFC and the amygdala, which is 
consistent with our study.13,16,17,69 As we only found a trend for lower mGluR5 availability in the 
caudate in a small subsample of non-smoking CU compared to non-smoking HC, it is possible that the 
small statistical power and the strong global effect associated with tobacco smoking in the overall 
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study sample may have masked cocaine-related effects on mGluR5 availability. Moreover, not all CU 
met criteria for dependence and 44% tested positive for cocaine in the urine toxicology. 
The question arises why cocaine use did not seem to alter mGluR5 availability while tobacco 
smoking did so in a very pronounced and global manner. In contrast to cocaine, nicotine has the ability 
to directly increase glutamate release by binding to nicotinic acetylcholine receptors (nAChR) that are 
located on presynaptic terminals of glutamatergic neurons in the PFC, ventral tegmental area (VTA), 
NAcc, amygdala, and the hippocampus.70 This might explain the strong smoking effect on mGluR5 
availability observed in the present study. In contrast, cocaine binds to monoamine transporters 
(dopamine, serotonin, noradrenaline), which are mainly localized in the basal ganglia but only show 
low density in most regions of the neocortex.71 Acute cocaine intake may therefore exert its function 
on glutamatergic transmission in a more indirect and less global manner compared to nicotine. Finally, 
in agreement with our findings, preclinical studies demonstrated specific cocaine-induced alterations 
of mGluR5 expression primarily in the NAcc core rather than globally.12-17 
Some limitations of the present report merit comment: i) Due to limited spatial resolution of 
PET imaging, we cannot fully exclude the possibility that CU may have exhibited subtle differences 
especially in the NAcc core region in comparison to controls. ii) The present study cannot 
conclusively answer if the reduced mGluR5 availability in smokers represents a pre-existent condition 
or is indeed acquired. iii) A PET study using the radioligand 18F-FPEB reported that the human 
cerebellum is not entirely devoid of mGluR5s.72 However, a more recent study with 18F-FPEB 
demonstrated that using the cerebellum as a reference region may be feasible to quantify mGluR5 
density.73 Additional support for negligible mGluR5 binding in the cerebellum comes from prior in 
vitro and in vivo studies with the radioligand 11C-ABP688.54,74 iv) The strong influence of recent 
tobacco use may have masked less pronounced cocaine-related effects on mGluR5 expression. 
In conclusion, tobacco smoking was associated with a globally lower mGluR5 density of 20%, 
while only a weak trend was found for decreased mGluR5 availability specifically in the caudate 
nucleus in a small non-smoking CU subsample. In particular, briefer smoking abstinence duration was 
associated with lower mGluR5 density pointing to the possibility of nicotine-induced down-regulation 
or internalization of mGluR5s. These findings provide evidence that mGluR5s are involved in nicotine 
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addiction and may have important implications with regard to the development of potential 
pharmacotherapies aimed at facilitating smoking cessation. If compounds targeting mGluR5s are 
effective in preventing relapses in human CU akin to preclinical findings remains to be determined. 
Since the systematic investigation of neuroadaptations in humans is much more complicated due to 
constraints in experimental manipulation that is only possible in preclinical research, it would be 
informative to apply multimodal imaging in human CU. For instance glutamate levels in the NAcc and 
PFC measured by means of magnetic resonance spectroscopy and how these levels are related to 
mGluR5 availability, PFC metabolism and perfusion in different stages of addiction (e.g., acute drug 
intake/relapse, craving, withdrawal) could be insightful to unmask neuroadaptations in drug-addicted 
humans.
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Figure Legends 
 
Figure 1. Regional differences in mGluR5 density (means and standard errors). (A) Normalized 
volumes of distribution (Vnorm) of 11C-ABP688 uptake did not differ between controls (n=17) and 
cocaine users (n=18) in 12 predefined regions of interest. (B) Smokers (n=24) showed significantly 
lower mGluR5 density in all regions of interest compared to non-smokers (n=11) irrespective of 
cocaine use. The percent difference of mGluR5 density in non-smokers and smokers ranged from 14 
to 21 percent. *Indicates significant differences (p<.0001). Ant. cingulate cortex, anterior cingulate 
cortex; ventrolat. prefrontal cortex, ventrolateral prefrontal cortex; dorsolat. prefrontal cortex, 
dorsolateral prefrontal cortex. 
 
Figure 2. Axial, sagittal, and coronal views of 11C-ABP688 binding. (A) 11C-ABP688 binding did not 
differ between controls and cocaine users. (B) Smokers exhibited a marked global reduction of 11C-
ABP688 binding compared to non-smokers. Vnorm = normalized volume of distribution. Crosshair 
position: (45, 39, 37; Montreal Neurological Institute brain atlas coordinates). 
 
Figure 3. Correlations between last cigarette use and mGluR5 availability in smokers (n=24). Longer 
duration of smoking abstinence (hours) was associated with higher mGluR5 availability. Vnorm, 
normalized volume of distribution of 11C-ABP688; Frontal VOI, average of Vnorm values of the OFC, 
ACC, MPFC, DLPFC, VLPFC; Striatum VOI, average of the Vnorm values of the caudate and 
putamen; Medial Temporal Lobe VOI, Vnorm values of the amygdala, parahippocampal gyrus, and the 
hippocampus; rp, Pearson’s product-moment correlation coefficient. 
 
Table 1. Demographic data (means and standard deviations, number of subjects and percent)       
  Controls (n=17) Cocaine users (n=18) Valuea pa df 
Age 36.24 (±8.34) 36.17 (±7.64) 0.03 0.98 33 
Body Mass Index (kg/m2) 23.72 (±2.77) 25.09 (±3.51) -1.28 0.21 33 
Years of education 10.53 (±1.94) 10.50 (±1.89) 0.05 0.96 33 
Beck Depression Index (BDI) 5.59 (±6.54) 5.89 (±3.91) -0.17 0.87 33
SCL-90-R Global Severity Index (GSI) 0.31 (±0.42) 0.38 (±0.24) -0.61 0.55 33
SCL-90-R Positive Symptom Distress Index (PSDI) 1.19 (±0.28) 1.28 (±0.25) -1.00 0.33 33 
SCL-90-R Positive Symptom Total (PST) 20.18 (±22.35) 25.72 (±14.09) -0.88 0.38 33 
Cocaine Craving Questionnaire (CCQ) (sum) - 20.06 (±6.03) - - - 
Age at cocaine use onset - 26.03 (±6.32) - - - 
Smoking Status (yes/no) 11, 6 (65, 35%) 13, 5 (72, 28%) 0.23 0.63 1 
Fagerström (sum) 2.55 (±2.73) 4.85 (±3.21) -1.87 0.08 22 
aIndependent T-test, bChi2-test for frequency data.         
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aConsumption per day/week captures the last six months, duration of use, and cumulative dose are 
averaged within the total group. Last consumption is averaged only for subjects who used the drug in 
the last six months. In this case, sample size is shown. The hair analysis was performed on two hair 
samples (each 3 cm in length) per participant capturing drug use over the last six months. 
Concentrations were averaged over the two samples. If the hair sample was not long enough, only one 
sample was analyzed (3 cm, 3 months). MDMA = 3,4-methylenedioxy-N-methylamphetamine; 
methylenedioxymethamphetamine, MDEA = methylenedioxyethylamphetamine, MDA = 3,4-
methylenedioxyamphetamine. 
 
Table 2. Drug use patterns (means and standard deviations) 
  Controls (n=17)  Cocaine users (n=18) 
      
Alcohol     
  Grams per week 88.10 (±62.90) 262.00 (±251.48) 
  Years of use 17.41 (±8.83) 17.58 (±6.46) 
      
Tobacco     
  Cigarettes per week 54.15 (±63.08) 85.19 (±73.74) 
  Years of use 11.32 (±11.09) 12.06 (±9.18) 
  Last consumption (hours) 14.47 (±22.36) n=11 123.86 (±320.35) n=13 
      
Cannabis     
  Grams per week 0.16 (±0.43) 1.07 (±1.92) 
  Years of use 4.79 (±7.59) 7.83 (±8.67) 
  Cumulative dose (grams) 177.23 (±290.81) 1563.85 (±2689.90)
  Last consumption (days) 50.76 (±74.39) n=5 3.81 (±2.14) n=8 
  Urine toxicology (pos./neg.) 2, 15 (12, 88%) 6, 12 (33, 67%) 
      
Cocaine     
  Times per week 0.00 (±0.00) 1.28 (±1.39) 
  Grams per week 0.00 (±0.00) 1.46 (±1.36)
  Years of use 0.00 (±0.00) 10.14 (±5.55) 
  Maximum dose (grams/day) - 3.94 (±2.89) 
  Cumulative dose (grams) 0.00 (±0.00) 1056.56 (±977.50) 
  Last consumption (days) - 7.60 (±6.84) 
  Cocaine in hair (pg/mg) 0.00 (±0.00) 18915 (±19665) 
  Benzoylecgonine in hair (pg/mg) 0.00 (±0.00) 3460 (±3575) 
  Ethylcocaine in hair (pg/mg) 0.00 (±0.00) 1490 (±2710) 
  Norcocaine in hair (pg/mg) 0.00 (±0.00) 395 (±500) 
  Urine toxicology (pos./neg.) 0, 100 (0, 100%) 8, 10 (44, 56%) 
      
Amphetamine     
  Grams per week 0.00 (±0.00) 0.0043 (±0.01)
  Years of use 0.00 (±0.00) 0.64 (±1.30) 
  Cumulative dose (grams) 0.00 (±0.00) 10.77 (±25.86) 
  Last consumption (days) - 76.00 (±40.22) n=3 
  Amphetamine in hair (pg/mg) 0.00 (±0.00) 12 (±30) n=3 
  Methamphetamine in hair (pg/mg) 0.00 (±0.00) 0.00 (±0.00) 
      
MDMA     
  Pills per week 0.00 (±0.00) 0.03 (±0.06) 
  Years of use 0.00 (±0.00) 3.58 (±4.94) 
  Cumulative dose (pills) 0.00 (±0.00) 24.88 (±63.74) 
  Last consumption (days) - 70.63 (±47.67) n=7 
  MDMA in hair (pg/mg) 0.00 (±0.00) 1644.44 (±4859.92) n=6 
  MDEA in hair (pg/mg) 0.00 (±0.00) 10.00 (±42.43) n=1 
  MDA in hair (pg/mg) 0.00 (±0.00) 68.33 (±259.28) n=2 
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Methods 
 
Methodology of the Urine Analysis 
Urine toxicology analysis comprised the compounds/substances tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and was assessed by a semi-quantitative 
Enzyme Multiplied Immunoassay method (Dimension RXL Max, Siemens, Erlangen, Germany). 
 
Methodology of the Hair Analysis 
If participants’ hair was long enough, one sample of six cm hair (from the scalp) was taken and 
subsequently divided into two subsamples of three cm length. The following compounds were assessed: 
cocaine, benzoylecgonine, ethylcocaine, norcocaine, amphetamine, methamphetamine, MDMA, MDEA, 
MDA, morphine, codeine, methadone EDDP (primary methadone metabolite), tramadol, and 
methylphenidate.  
For our routine protocol for drugs of abuse analysis a three step washing procedure with water (2 
minutes shaking, 15ml), acetone (2min., 10ml) and finally hexane (2min., 10ml) of hair was performed. 
Then the hair samples were dried at ambient temperatures, cut into small snippets and extracted in two 
steps, first with methanol (5ml, 16hours, ultrasonication) and a second step with 3 ml MeOH acidified 
with 50 µL hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried and the residue 
reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical grade) in water. As 
internal standards deuterated standards of the following compounds were used, added as mixture of the 
following compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-d3, morphine-d3, MAM-d3, 
codeine-d3, dihydrocodeine-d3, amphetamine-d6, methamphetamine-d9, MDMA-d5. MDEA-d6, MDA-
d5, methadone-d9, EDDP-d3, methylphenidate-d9, tramadol-d3, oxycodone-d3, and ephedrine-d3. All 
deuterated standards were from ReseaChem (Burgdorf, Switzerland), the solvents for washing and 
extraction were of analysis grade and obtained from Merck (Darmstadt, Germany); LC-solvents were of 
HPLC grade and were obtained from Sigma Aldrich (Buchs, Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V 
ion source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), with a 
Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, 
Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ 
POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of 1mM ammonium formate buffer adjusted to 
pH 3,5 with formic acid (eluent A) and acetonitrile containing 1mM ammonium formate and 1 mM 
formic acid (eluent B). The Analysis was performed in MRM mode with two transitions per analyte and 
one transition for each deuterated internal standard, respectively. 
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Table S1. Independent t-tests of age, tobacco use and brain regions for non-smokers and smokers (means and standard deviations) 
  Nonsmokers (n = 11) Smokers (n = 24) t-value df % difference Cohen's d 
Age 38.09 (± 6.07) 35.33 (± 8.54) -0.96 33 - - 
Cigarettes per week 0.00 (± 0.00) 101.83 (± 61.72) 8.08* 33 - - 
Smoking duration (years) 0.00 (± 0.00) 16.02 (± 7.94) 10.01* 33 - - 
Age at smoking onset - 19.31 (± 7.40) - - - - 
Last cigarette (hours) - 73.73 (± 238.45) - - - - 
Anterior cingulate cortex 1.93 (± 0.24) 1.56 (± 0.19) -4.98 33 -19 ± 9.96% 1.39* 
Caudate 1.95 (± 0.18) 1.55 (± 0.20) -5.75 33 -21 ± 10.14% 1.50* 
Insula 1.89 (± 0.21) 1.52 (± 0.17) -5.53 33 -20 ± 9.04% 1.47* 
Putamen 1.83 (± 0.18) 1.49 (± 0.17) -5.42 33 -18 ± 9.17% 1.46* 
Medial prefrontal cortex 1.84 (± 0.22) 1.48 (± 0.16) -5.30 33 -19 ± 8.91% 1.44* 
Parahippocampal gyrus 1.76 (± 0.16) 1.43 (± 0.18) -5.24 33 -19 ± 9.96% 1.43* 
Orbitofrontal cortex 1.76 (± 0.19) 1.43 (± 0.17) -5.18 33 -19 ± 9.55% 1.42* 
Ventrolater prefrontal cortex 1.71 (± 0.19) 1.41 (± 0.15) -5.28 33 -18 ± 8.60% 1.44* 
Amygdala 1.75 (± 0.17) 1.41 (± 0.19) -5.08 33 -19 ± 10.82% 1.41* 
Dorsolateral prefrontal cortex 1.64 (± 0.20) 1.34 (± 0.13) -5.31 33 -18 ± 7.84% 1.44* 
Hippocampus 1.64 (± 0.18) 1.33 (± 0.17) -5.00 33 -19 ± 10.12% 1.39* 
Thalamus 1.51 (± 0.11) 1.30 (± 0.10) -5.30 33 -14 ± 6.91% 1.44* 
*p<.0001            
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Figure Legend 
 
Figure S1. Regional differences in mGluR5 density (means and standard errors) in controls and cocaine 
users depend on smoking status. (A) Normalized volumes of distribution (Vnorm) of 11C-ABP688 uptake 
differed significantly between non-smokers and smokers in all regions of interest irrespective of whether 
they used cocaine (a mixed-effect ANOVA revealed significant main effects of group [F(3,31)=11.07, 
p<.0001] and brain region [F(11,341)=125.46, p<.0001]). More specifically, smoking controls (p<.0001, 
Bonferroni-corrected post hoc comparisons) and smoking cocaine users (p<.01) had significantly lower 
mGluR5 density than non-smoking controls, and smoking controls (p<.01) and by trend smoking cocaine 
users (p=.069) had lower mGluR5 density than non-smoking cocaine users. **Indicates significant 
differences (p<.0001). (B) Percent difference in Vnorm between non-smoking controls (n=6), smoking 
controls (n=11), non-smoking cocaine users (n=5), and smoking cocaine users (n=13). **Indicates 
significant differences (p<.0001), *stands for (p<.01). Ant. cingulate cortex, anterior cingulate cortex; 
ventrolat. prefrontal cortex, ventrolateral prefrontal cortex; dorsolat. prefrontal cortex, dorsolateral 
prefrontal cortex. 
 
 
Figure S2. Regional differences in mGluR5 density (means and standard errors) in never smokers 
(n=11), light smokers (n=12; FTND score <4) and heavy smokers (n=12; FTND score ≥4). Never 
smokers had significantly higher mGluR5 availability than light (p<.01) and heavy smokers (p<.0001), 
while light and heavy smokers did not significantly differ from each other (p=.47) (main effects of group 
[F(2,32)=16.50, p<.0001; linear contrast p<.0001] and brain region [F(11,352)=125.19, p<.0001] in 
mixed-effect ANOVA). FTND, Fagerström Test for Nicotine Dependence; Vnorm, normalized volumes of 
distribution of 11C-ABP688 uptake. **Indicates significant differences (p<.0001), *stands for (p<.01). 
Ant. cingulate cortex, anterior cingulate cortex; ventrolat. prefrontal cortex, ventrolateral prefrontal 
cortex; dorsolat. prefrontal cortex, dorsolateral prefrontal cortex. 
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